Luteinizing hormone releasing hormone agonists induce ovulation in hypophysectomized proestrous rats: direct ovarian effect

The spatiotemporal hormonal orchestration of human folliculogenesis, early embryogenesis and blastocyst implantation

The early reproductive events starting with folliculogenesis and ending with blastocyst implantation into the uterine endometrium are regulated by a complex interplay among endocrine, paracrine and autocrine factors. This review examines the spatiotemporal integration of these maternal and embryonic signals that are required for successful reproduction. In coordination with hypothalamic-pituitary-gonadal (HPG) hormones, an intraovarian HPG-like axis regulates folliculogenesis, follicular quiescence, ovulation, follicular atresia, and corpus luteal functions. Upon conception and passage of the zygote through the fallopian tube, the contribution of maternal hormones in the form of paracrine secretions from the endosalpinx to embryonic development declines, with autocrine and paracrine signaling becoming increasingly important as instructional signals for the differentiation of the early zygote/morula into a blastocyst. These maternal and embryonic signals include activin and gonadotropin-releasing hormone 1 (GnRH1) that are crucial for the synthesis and secretion of the 'pregnancy' hormone human chorionic gonadotropin (hCG). hCG in turn signals pre-implantation embryonic cell division and sex steroid production required for stem cell differentiation, and subsequent blastulation, gastrulation, cavitation and blastocyst formation. Upon reaching the uterus, blastocyst hatching occurs under the influence of decreased activin signaling, while the attachment and invasion of the trophoblast into the endometrium appears to be driven by a decrease in activin signaling, and by increased GnRH1 and hCG signaling that allows for tissue remodeling and the controlled invasion of the blastocyst into the uterine endometrium. This review demonstrates the importance of integrative endocrine, paracrine, and autocrine signaling for successful human reproduction.

RFamide-related peptide and messenger ribonucleic acid expression in mammalian testis: association with the spermatogenic cycle

RFamide-related peptide (RFRP), the mammalian homolog of avian gonadotropin-inhibitory hormone, has a pronounced suppressive action on the reproductive axis across species. In mammals, RFRP acts directly on GnRH neurons, and likely at the level of the pituitary, to inhibit gonadotropin secretion. In the present study, we examined whether RFRP might act outside of mammalian brain on reproductive tissues directly. Using RT-PCR and in situ hybridization, we found that both RFRP and its receptors [G protein-coupled receptor (GPR) 147 and GPR74] are expressed in the testis of Syrian hamster. These results were confirmed and extended using double- and triple-label immunohistochemistry. RFRP expression was observed in spermatocytes and in round to early elongated spermatids. Significant expression of RFRP was not seen in Leydig cells. GPR147 protein was observed in myoid cells in all stages of spermatogenesis, pachytene spermatocytes, maturation division spermatocytes, and in round and late elongated spermatids. GPR74 proteins only appeared in late elongated spermatids. Additionally, we found that RFRP and its receptor mRNA are markedly altered by day length and reproductive condition. These findings highlight a possible novel autocrine and/or paracrine role for RFRP in Syrian hamster testis, potentially contributing to the differentiation of spermatids during spermiogenesis.

Gonadotropin-inhibitory hormone and its receptor in the avian reproductive system

Many hormones that are classified as neuropeptides are synthesized in vertebrate gonads in addition to the brain. Receptors for these hormones are also expressed in gonadal tissue; thus there is potential for a highly localized autocrine or paracrine effect of these hormones on a variety of gonadal functions. In the present study we focused on gonadotropin-inhibitory hormone (GnIH), a neuropeptide that was first discovered in the hypothalamus of birds. We present different lines of evidence for the synthesis of GnIH and its receptor in the avian reproductive system including gonads and accessory reproductive organs by studies on two orders of birds: Passeriformes and Galliformes. Binding sites for GnIH were initially identified via in vivo and in vitro receptor fluorography, and were localized in ovarian granulosa cells along with the interstitial layer and seminiferous tubules of the testis. Furthermore, species-specific primers produced clear PCR products of GnIH and GnIH receptor (GnIH-R) in songbird and quail gonadal and other reproductive tissues, such as oviduct, epididymis and vas deferens. Sequencing of the PCR products confirmed their identities. Immunocytochemistry detected GnIH peptide in ovarian thecal and granulosa cells, testicular interstitial cells and germ cells and pseudostratified columnar epithelial cells in the epididymis. In situ hybridization of GnIH-R mRNA in testes produced a strong reaction product which was localized to the germ cells and interstitium. In the epididymis, the product was also localized in the pseudostratified columnar epithelial cells. In sum, these results indicate that the avian reproductive system has the capability to synthesize and bind GnIH in several tissues. The distribution of GnIH and its receptor suggest a potential for autocrine/paracrine regulation of gonadal steroid production and germ cell differentiation and maturation.

Local production of the gonadotropic hormones in the rat ovary

The gonadotropic hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are synthesized by and released from the anterior pituitary in response to the hypothalamic gonadotropin-releasing hormone (GnRH) signaling. In the female, LH and FSH affect folliculogenesis, ovarian steroid production, oocyte maturation, ovulation and corpus luteum formation. We have recently studied the expression of GnRH and its receptor in the rat ovary and found organ-specific, estrous cycle-dependant, fluctuations. Subsequently, we wished to determine whether rat ovaries also express gonadotropic hormones. Using RT-PCR, we detected LHbeta, FSHbeta and the common alpha-subunit mRNA's in intact follicles, theca cells, corpora lutea and in meiotically competent and incompetent oocytes. Granulosa cells, however, express mRNA's for LHbeta and the common alpha-subunit, but not for FSHbeta. We cloned and sequenced the ovarian LHbeta transcript and found it to be longer (2.3kb) than the one produced by pituitary gonadotropes (0.8kb), due to a longer 5'-UTR. We studied the regulation of ovarian LHbeta mRNA in sexually immature female rats administered with pregnant mare serum gonadotropin (PMSG) and in adult cyclic rats. PMSG administration caused a significant decrease in LHbeta mRNA expression, detected by real-time PCR. Similarly, LHbeta mRNA levels were lower on estrous morning versus proestrous evening. Interestingly, ovarian content of LH remained unchanged following hypophysectomy, although ovarian weight was immensely reduced. Taken together, it seems probable that ovarian LH is heterologously/homologously regulated by pituitary, and possibly also by local gonadotropins. Thus, these findings may imply the existence of a local GnRH-gonadotropin axis in the mammalian ovary that may be involved in the management of processes that lead to ovulation.

Effects of dose and duration of continuous GnRH-agonist treatment on induction of estrus in beagle dogs: competing and concurrent up-regulation and down-regulation of LH release

Dose-response estrus-induction trials were conducted during anestrus in 93 treated and 6 control bitches, a continuous administration of the GnRH-agonist lutrelin with a potency 150 x GnRH, and at six different doses from 0.2 to 4.8 microg/kg/d for 7-14 days in 15 groups of six to eight dogs each in defined stages of natural or pharmacologically determined anestrus. Agonist treatment induced clinically and cytologically normal proestrus (in 89% of cases) within 4.8 +/- 0.2 x days, and resulted in behavioral estrus (71%), spontaneous late-proestrus LH (and FSH) surges, ovulation (59%) and pregnancy (44%) in a dose dependent manner. Outcomes of ovulation and pregnancy in most cases required that the dose be sufficiently large enough to routinely stimulate a large initial increase in LH and FSH (i.e., > or = 0.6 microg/kg/d), and of sufficient duration (i.e., > 7 days) to ensure that supra-basal gonadotropin levels persistedntil no longer needed for spontaneous continuation of an induced proestrus. Success additionally required that the GnRH dose be modest enough (i.e., < 1.8 microg/kg/d) to not excessively down-regulate spontaneous pre-ovulatory surge release of gonadotropin or be removed shortly before or at the time when the LH surges typically occurred (10-13 days after initiation of treatment). The 1.8 microg dose was compared to saline to assess the time course of its down-regulation action on serum LH in six ovariohysterectomized bitches compared to four saline-related controls. Results in intact bitches receiving the 1.8-microg doses demonstrated an LH-releasing effect for 10-11 days that overlapped a period of obvious down-regulation seen with the same dose after 3 days in the ovariohysterectomized bitches. In the latter, however, complete down-regulation to anestrus-like values did not occur until after 18-21 days of treatment. A dose of 0.6 microg/kg/d for 12 days yielded the best estrus-induction results, including pregnancy rates of 100% in six bitches treated in natural-anestrus bitches, six bitches in which anestrus had been advanced by a luteolytic prostaglandin treatment and in six bitches in which anestrus had been extended by progesterone implants administered for 3 months. Although lutrelin is not commercially available, these results provide guidelines for the development of estrus-inducing protocols with other GnRH-agonists of known biopotencies.

Differential gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acid expression patterns in different tissues of the female rat across the estrous cycle

GnRH, the main regulator of reproduction, is produced in a variety of tissues outside of the hypothalamus, its main site of synthesis and release. We aimed to determine whether GnRH produced in the female rat pituitary and ovaries is involved in the processes leading to ovulation. We studied the expression patterns of GnRH and GnRH receptor (GnRH-R) in the same animals throughout the estrous cycle using real-time PCR. Hypothalamic levels of GnRH mRNA were highest at 1700 h on proestrus, preceding the preovulatory LH surge. No significant changes in the level of hypothalamic GnRH-R mRNA were detected, although fluctuations during the day of proestrus are evident. High pituitary GnRH mRNA was detected during the day of estrus, in the morning of diestrus 1, and at noon on proestrus. Pituitary GnRH-R displayed a similar pattern of expression, except on estrus, when its mRNA levels declined. Ovarian GnRH mRNA levels increased in the morning of diestrus 1 and early afternoon of proestrus. Here, too, GnRH-R displayed a somewhat similar pattern of expression to that of its ligand. To the best of our knowledge, this is the first demonstration of a GnRH expression pattern in the pituitary and ovary of any species. The different timings of the GnRH peaks in the three tissues imply differential tissue-specific regulation. We believe that the GnRH produced in the anterior pituitary and ovary could play a physiological role in the preparation of these organs for the midcycle gonadotropin surge and ovulation, respectively, possibly via local GnRH-gonadotropin axes.

Novel expression of gonadotropin subunit genes in oocytes of the gilthead seabream (Sparus aurata)

It is widely believed that FSH and LH, which are known to play key roles in controlling the production of functional oocytes in vertebrates, are synthesized and secreted exclusively by the anterior pituitary. Here we present evidence for the novel expression of FSHbeta, LHbeta, and the common glycoprotein-alpha (Cgalpha) in the gilthead seabream ovary. Using in situ hybridization and immunocytochemistry, FSHbeta was detected in primary-growth and secondary-growth-I oocytes, LHbeta was found in secondary-growth oocytes, and Cgalpha was observed in both primary and secondary-growth oocytes. Northern blot analyses demonstrated that Fshbeta transcript is 0.6 kb in both pituitary and ovary, whereas the ovarian Lhbeta transcript (1.1 kb), unexpectedly, is longer than the known pituitary Lhbeta transcript (0.6 kb). Sequence analyses revealed that ovarian Lhbeta is driven by a different promoter than pituitary Lhbeta, which generates an additional 459 bases at the distal portion of the 5'-untranslated region of the ovarian Lhbeta. Furthermore, using in vitro ovarian fragment incubation, we demonstrated that mammalian GnRH analog agonist enhanced the expression of ovarian Fshbeta (up to 2.7-fold), Lhbeta (up to 1.4-fold), Cgalpha (up to 1.8-fold), and the secretion of ovarian LH (up to 2.2-fold). In contrast, GnRH antagonist, analog E, suppressed the secretion of ovarian LH. Our findings suggest that a GnRH-gonadotropin axis is present in the gilthead seabream ovary and that FSH and LH, the well-characterized pituitary hormones, may have prominent novel roles in teleost intraovarian communication between oocytes and ovarian follicle cells.

Promoter sequences targeting tissue-specific gene expression of hypothalamic and ovarian gonadotropin-releasing hormone in vivo

Molecular mechanisms directing tissue-specific expression of gonadotropin-releasing hormone (GnRH) are difficult to study due to the paucity and scattered distribution of GnRH neurons. To identify regions of the mouse GnRH (mGnRH) promoter that are critical for appropriate tissue-specific gene expression, we generated transgenic mice with fragments (-3446/+23 bp, -2078/+23 bp, and -1005/+28 bp) of mGnRH promoter fused to the luciferase reporter gene. The pattern of mGnRH promoter activity was assessed by measuring luciferase activity in tissue homogenates. All three 5'-fragments of mGnRH promoter targeted hypothalamic expression of the luciferase transgene, but with the exception of the ovary, luciferase expression was absent in non-neural tissues. High levels of ovarian luciferase activity were observed in mice generated with both -2078 and -1005 bp of promoter. Our study is the first to define a region of the GnRH gene promoter that directs expression to both neural and non-neural tissues in vivo. We demonstrate that DNA sequences contained within the proximal -1005 bp of the mGnRH promoter are sufficient to direct mGnRH gene expression to both the ovary and hypothalamus. Our results also suggest that DNA sequences distal to -2078 bp mediate the repression of ovarian GnRH.

In vitro steroid production by follicles of frog Rana esculenta: mammalian gonadotropin-releasing hormone effects

The effects of mammalian gonadotropin-releasing hormone on ovarian release of progesterone, androgens and estradiol-17 beta were studied in vitro by a superfusion system carried out on follicles of adult female Rana esculenta, collected at different periods of the annual reproductive cycle. The follicles were superfused with medium alone, pituitary, mammalian gonadotropin-releasing hormone, or pituitary plus mammalian gonadotropin-releasing hormone. For follicles obtained in the prereproductive period, pituitary plus mammalian gonadotropin-releasing hormone increased the estradiol values much more than pituitary alone. In the reproductive period, pituitary alone increased the estradiol values much more than pituitary plus mammalian gonadotropin-releasing hormone. For follicles obtained in the recovery period, mammalian gonadotropin-releasing hormone alone stimulated the highest estradiol production, and pituitary plus mammalian gonadotropin-releasing hormone increased the estradiol values much more than pituitary alone. The results reported here suggest that mammalian gonadotropin-releasing hormone and/or pituitary have a direct effect on ovarian estradiol secretion, and that this effect varies with the annual reproductive cycle.

Passive immunization of the pig against gonadotropin releasing hormone during the follicular phase of the estrous cycle

Three experiments were conducted to determine the effects of passively immunizing pigs against gonadotropin releasing hormone (GnRH) during the follicular phase of the estrous cycle. In Experiment 1, sows were given GnRH antibodies at weaning and they lacked estrogen secretion during the five days immediately after weaning and had delayed returns to estrus. In Experiment 2, gilts passively immunized against GnRH on Day 16 or 17 of the estrous cycle (Day 0 = first day of estrus) had lower (P<0.03) concentrations of estradiol-17beta than control gilts, and they did not exhibited estrus at the expected time (Days 18 to 22). When observed three weeks after passive immunization, control gilts had corpora lutea present on their ovaries, whereas GnRH-immunized gilts had follicles and no corpora lutea. The amount of GnRH antiserum given did not alter (P<0.05) serum concentrations of LH or pulsatile release of LH in sows and gilts. In Experiment 3, prepuberal gilts were given 1,000 IU PMSG at 0 h and GnRH antiserum at 72 and 120 h. This treatment lowered the preovulatory surge of LH and FSH, but it did not alter serum estradiol-17beta concentrations, the proportion of pigs exhibiting estrus, or the ovulation rate. These results indicate that passive immunization of pigs against GnRH before initiation of or during the early part of the follicular phase of the estrous cycle retards follicular development, whereas administration of GnRH antibodies during the latter stages of follicular development does not have an affect. Since the concentration of antibodies was not high enough to alter basal or pulsatile LH secretion, the mechanism of action of the GnRH antiserum may involve a direct ovarian action.

Rat oocyte maturation: role of calcium in hormone action

We studied the role of extracellular calcium (Ca0) in oocyte maturation and oocyte-cumulus cells interaction in rat follicles in vitro. Luteinizing hormone (LH) or a gonadotropin-releasing hormone analog (GnRHa) induced full maturation at [Ca0] = 1.3 mM. At [Ca0] = 0.6 mM, maturation induced by LH or GnRHa was inhibited by 65%. Chelatin of [Ca0] resulted in 45% maturation and neither hormone caused a further increase of maturation. [Ca0] = 20 mM enhanced the response to suboptimal concentrations of GnRHa but inhibited that to LH. Divalent cation ionophores caused [Ca0]-dependent maturation, which was fully inhibited by dibutyryl cAMP. Changes in [Ca0] also affected oocyte-cumulus interaction. At [Ca0] = 1.3 mM, either LH or GnRHa caused partial dispersion of the cumulus. Chelation of [Ca0] also resulted in an almost complete dispersion of the cumulus. The ionophores, however, caused maturation with the oocyte-cumulus complex preserved intact. Our data suggest that GnRHa may induce maturation via cAMP-sensitive calcium mobilization into the oocyte-cumulus-granulosa complex.

Effect of a teleost GnRH analog on steroidogenesis by the follicle-enclosed goldfish oocytes, in vitro

The influence of an agonist analog of teleost GnRH [(D-Arg6, Trp7, Leu8, Pro9-NEt)-GnRH; tGnRH-A] on steroidogenesis was studied in prophase-I arrested, follicle-enclosed, goldfish oocytes in vitro. Incubation of the follicles with carp gonadotropin (GtH) significantly increased production of 17 alpha-hydroxyprogesterone (HP) and testosterone following 24 hr of incubation in vitro. Concomitant incubation with tGnRH-A (10(-7) M) significantly attenuated the dose-related increase in GtH-induced testosterone production, but was without effect on the GtH-induced HP level. Time course studies indicated that tGnRH-A exerted its maximum inhibitory action on the GtH-induced testosterone production during the initial 8 hr of incubation in vitro. The inhibition of GtH-induced testosterone production by tGnRH-A was dose dependent with an ED50 of 1.39 +/- 2.88 nM. A significantly higher testosterone level was obtained in the incubation media containing HP as substrate; concomitant treatment with tGnRH-A reduced the conversion of HP to testosterone. The incubation media also contained low, but measurable levels of 17 alpha-hydroxy-20 beta-dihydroprogesterone (DHP), which increased in the presence of 3-isobutyl-methyl-xanthine; lower levels of DHP were obtained in the groups incubated with tGnRH-A. In view of our present findings and previous observations concerning inhibitory effects of tGnRH-A on the progestogen and GtH-induced reinitiation of meiosis in the follicle-enclosed goldfish oocytes (H. R. Habibi, G. Van Der Kraak, E. Bulanski, and R. E. Peter, Amer. J. Physiol. 255, R268-R273 (1988] the influence of testosterone on the GtH- and DHP-induced meiosis in vitro was also studied. Testosterone (1 micrograms/ml) enhanced both GtH- and DHP-induced oocyte meiosis in the goldfish oocytes. Testosterone alone was also found to significantly increase oocyte meiosis in the goldfish oocytes in a dose-related fashion. The present findings demonstrate an inhibitory effect of a GnRH agonist on GtH-induced testosterone production in goldfish oocytes and suggest that tGnRH-A might influence oocyte meiosis in part by influencing steroidogenesis.

Effect of Des-Gly10-(im-Bzl-D-His6)LHRH-ethylamide on hypophysial gonadotrophs and ovary of the juvenile frog Rana cyanophlyctis (Schn.)

The effects of synthetic luteinizing hormone-releasing hormone (LHRH) (0.01 and 0.1 microgram) agonist on pituitary and ovary were studied in the juvenile frog Rana cyanophlyctis with respect to their body weights. Injections (ip) were given 6 days a week for 30 days and frogs were sacrificed on the 31st day. The pituitary sections were stained with AB-PAS-OG technique. The staining intensity, cytoplasmic granulations, and length of hypophysial gonadotrophs (B2 cells) were increased (P less than 0.05) due to LHRH treatment. In controls, the B2 cells were small and faintly stained. Treatment with LHRH (0.01 or 0.1 microgram) once a day or twice a day (0.01 microgram) to frogs weighing less than 6 g body weight had no effect on gonadosomatic index (GSI) or size frequency distribution of oocytes even though gonadotrophs were hypertrophied and hyperactive. Whereas administration of LHRH (0.01 or 0.1 microgram) once a day to frogs weighing around 8 g caused a significant (p less than 0.05) increase in ovary weight, GSI, and diameter of the largest oocytes. Further, oocytes were recruited to second growth phase (i.e., incorporation of yolk in oocytes) due to LHRH treatment. The above findings suggest that synthetic LHRH agonist has the stimulatory effect on oocyte growth and recruitment of vitellogenic oocytes in juvenile frogs weighing around 8 g. The LHRH induces precocious maturity by incorporating yolk in oocytes. The pituitary responsiveness to LHRH agonist is also evident in juvenile frogs. The ovarian receptivity/responsiveness to endogenous gonadotrophins seems to progressively increase with the increase in the body weight of the juvenile frogs.

Calcium-dependent actions of gonadotropin-releasing hormone agonist and luteinizing hormone upon cyclic AMP and progesterone production in rat ovarian granulosa cells

The Ca2+ dependency of the direct stimulatory effect of the gonadotropin-releasing hormone (GnRH) agonist analog [D-Ser(t-Bu)6]des-Gly10-GnRH-N-ethylamide (GnRHa) on progesterone production was investigated and compared to that of luteinizing hormone (LH) in rat granulosa cells from preovulatory follicles. Removal of extracellular Ca2+ by EGTA, or the use of the Ca2+ channel blockers verapamil and La3+, resulted in complete inhibition of GnRHa-induced progesterone production and a partial inhibition of LH-stimulated progesterone production (80, 80 and 50% inhibition respectively for EGTA, verapamil and La3+). Removal of extracellular Ca2+ increased the ED50 for LH-induced cAMP production by four-fold (from 80 to 330 ng/ml) and decreased maximal nucleotide formation by 44%. LH-induced cAMP production was also inhibited partially by verapamil (35%) at 10(-4) M drug concentration. GnRHa had no effect on cAMP production in the presence or absence of Ca2+. GnRHa and LH were found to have maximal effects on progesterone production at about 0.5 mM of Ca2+ in the incubation medium. On the other hand the stimulatory effect of dibutyryl cAMP [Bu)2cAMP) on progesterone production showed little dependency on extracellular Ca2+. The calmodulin antagonist trifluoperazine (TFP) caused concentration-dependent inhibition of the stimulatory action of GnRHa and LH on progesterone production with IC50 values of 3 and 8 microM, respectively. The stimulatory effect of (Bu)2cAMP on progesterone synthesis was attenuated by verapamil and TFP. These results indicate that the direct stimulatory effect of GnRH on ovarian progesterone production is absolutely dependent on Ca2+.(ABSTRACT TRUNCATED AT 250 WORDS)

Mechanisms of action of gonadotropin releasing hormone on rat granulosa cells

To elucidate the mechanisms of stimulatory actions of GnRH on rat granulosa cells (GC), we have compared the actions of a GnRH agonist with those of a tumor-promoting phorbol ester, 12-0-tetradecanoylphorbol 13-acetate (TPA) and Ca+2 ionophore, A23187. GC were obtained from immature (28-29 days old) rats 48 h after injection of 20 IU PMSG. Following prelabeling with 3[H]arachidonic acid (AA), the cells were incubated with the test substances for 10 min and AA release determined. A GnRH agonist, [D-Ala6, des-Gly-NH2(10)] GnRH ethylamide (GnRHa; 10 ng/ml) increased AA release 175% compared to the control value. AA release in the presence of GnRHa was larger than that due to 1 microM A23187 or 40 nM TPA alone. A23187 or TPA increased GnRHa-stimulated AA release further. GC were incubated with the test substances for longer time periods, i.e., up to 5 h. GnRHa caused a 4-fold increase in prostaglandin (PG) synthase activity at 5 h. GnRHa increased PGE accumulation to the same extent as TPA, but only increased PG synthase activity about half as much. In combination with TPA, GnRHa had no influence on TPA-stimulated PG synthase activity, but increased PGE accumulation to levels comparable to those with A23187 plus TPA. GnRHa caused a 2.5 fold increase in progesterone (P) accumulation, which was the same as TPA. P accumulation in the presence of GnRHa was affected by neither A23187 nor TPA. These data indicate that the combination of TPA and A23187 can substitute for GnRH action on PGE and P accumulation in rat GC.

LHRH stimulates plasminogen activator and inhibits steroid production by granulosa cells of adult rat Graafian follicles

We studied the effects of LHRH and its analogs on plasminogen activator production and progesterone and estradiol secretion by granulosa cells isolated from adult rat Graafian follicles. LHRH and its agonist ([des- -Gly10,D-Trp6,Pro9-NHEt]LHRH) stimulated small but significant increases in plasminogen activator production. This stimulatory action of LHRH was blocked by the addition of the specific antagonist ([D- pGlu1,D-Phe2,D-Trp3,6]LHRH). In contrast, LHRH treatment had no significant effect on basal steroid production by granulosa cells of Graafian follicles cultured for 2-6 days. However, LHRH decreased the FSH-stimulated steroidogenesis. This inhibitory effect of LHRH on steroidogenesis was abolished by concomitant addition of the LHRH antagonist. The results show that LHRH has a stimulatory effect on plasminogen activator production and a suppressive action on steroidogenesis in granulosa cells isolated from Graafian follicles of adult rats.

In vitro study of the direct ovarian effects of gonadotropin-releasing hormone (GnRH) in the frogs, Rana pipiens and Rana catesbeiana

Ovaries from the leopard frog, Rana pipiens, and bullfrog, R. catesbeiana, were used to study potential direct extrapituitary effects of gonadotropin-releasing hormone (GnRH). GnRH alone did not alter steroid secretion from ovaries in either species. Ovarian fragments containing mature follicles from R. pipiens were incubated in several submaximal doses of homologous pituitary homogenate or purified bullfrog luteinizing hormone (LH) together with 1000 ng/ml GnRH. The addition of GnRH failed to alter testosterone (T) or progesterone secretion or germinal vesicle breakdown over a wide dose range of gonadotropin. The effects of supramaximal doses of pituitary homogenate on R. pipiens and the effects of homologous LH on T secretion by fragments of R. catesbeiana ovaries were also unaffected by the presence of GnRH. The lack of a GnRH effect on the dynamics of T secretion in the bullfrog was further confirmed in a superfusion system with homologous pituitary homogenate. This study fails to demonstrate an action of GnRH at the level of the ovary in two ranid species.

Gonadotropin-releasing hormone as a modulator of ovarian function

GnRH and its agonist analogs exert direct inhibitory and stimulatory effects on the ovaries of animals from several species. In the immature follicle, GnRH inhibits the actions of FSH on an integrated array of biochemical responses that lead to follicular development and corpus luteum formation. GnRH also suppresses gonadotropin action in mature follicles, and stimulates certain ovarian processes such as steroidogenesis and oocyte maturation. The inhibitory and stimulatory effects of GnRH are mediated through the binding of the peptide to high-affinity receptors in granulosa and thecal cells. Recent studies have shown that GnRH action in the ovary is dependent upon calcium mobilization and probably operates through stimulation of phospholipid turnover and activation of protein kinase C.

LRFD6a has a dose-related stimulatory or inhibitory effect on the ovary in normal luteal phase women

A dose response curve for LRFD6a-a potent LRF agonist-was established in normal midluteal phase women. At low doses (3-10 micrograms) an acute stimulatory effect on gonadotropins and ovarian steroidogenesis of estradiol and progesterone was observed. Despite large increases in circulating gonadotropins following the highest dose (30 micrograms LRFD6a), no acute changes in plasma steroids were noted. A sharp drop in progesterone was present after 3 days, with significant shortening of the cycle in 3 of 4 subjects in the group. While the stimulatory effect may be due to gonadotropin release and local action, the luteolytic effect observed is suggested to be a consequence of the direct inhibitory effect of the analog on ovarian function.

Comparison between the steroidogenic responses after pulsatile and continuous administration of gonadotrophin releasing hormone to superfused rat follicles

Gonadotrophin releasing hormone (GnRH) exhibits both stimulatory and inhibitory effects on the ovarian tissue in the rat. For the action of GnRH on the pituitary, the mode of administration is of utmost importance. The binding characteristics and regulation of the GnRH receptors found in the ovary are very similar to those of the pituitary. The aim of the present study was to compare the steroidogenic response of superfused, preovulatory rat follicles to continuous and pulsatile administration of a GnRH analogue (GnRHa). The results obtained with a single pulse of luteinizing hormone (LH) served as a control. Repeated pulses (1 pulse X h-1) or continuous administration of GnRHa was found to be more effective than a single pulse of GnRHa. The effect of GnRHA, irrespective of the mode of administration, was most pronounced on the secretion of 20 alpha-OH-progesterone (20 alpha-OHP). Also the release of testosterone (T) and oestradiol (E2) was stimulated but to a lesser extent. In comparison to LH, the GnRHa response was delayed and without detectable release of cyclic AMP (cAMP). These results illustrate that pulses of GnRH stimulate the steroidogenesis in preovulatory follicles. In contrast to the effects of GnRHa on the pituitary, the modes of administration seem to be of less importance for the stimulation of the rat ovary.

Corticotropin releasing factor increases the adrenocortical responsiveness to adrenocorticotropin

In the course of studying the plasma adrenocorticotropic hormone (ACTH) and corticosterone responses to synthetic corticotropin releasing factor (CRF), we noted some disparity in the responses. A higher dose (20 micrograms compared with 5 micrograms per rat i.a.) produced an equal plasma ACTH but greater plasma corticosterone response in adult male rats. Thus, we examined the possibility that CRF increases adrenocortical responsiveness to ACTH. CRF significantly (p less than 0.0005) increased the plasma corticosterone response to ACTH in rats pretreated with dexamethasone. Thus, synthetic CRF increases corticosterone secretion in rats not only by stimulating ACTH secretion, but also by increasing the adrenocortical responsiveness to ACTH.

Cyclic response of hypophysectomized rats to ovulation induced by LHRH agonist: mediation by prostaglandins

Further confirmation that the LHRH/LHRH agonist-induced ovulation in the hypophysectomized (hypx) rat is due to a direct ovarian effect and not mediated by LH release from residual pituitary tissue or other CNS sites is provided by the persistence of this effect despite concomitant median eminence lesion or passive immunization to LH. Adrenalectomy did not affect the ovulatory activity of the LHRH agonist, D-Trp6-N alpha MeLeu7-DesGly10-Pro9-NHEt-LHRH (Wy-40,972), in the hypx rat. Prior administration of a potent LHRH antagonist blocked ovulation induced in hypx proestrous rats by Wy-40,972 but not by LH-S19. Ovulation can be induced by Wy-40,972 one day earlier (e.g. metestrus) in the intact rat than it can in the hypx rat. Results in the hypx metestrous rat indicate that the ovulatory responsiveness of the intact rat at this stage of the cycle may occur by complementary action of Wy-40,972-stimulated endogenous LH release and a direct ovarian effect of the agonist. Prostaglandins (PG) are involved in the ovulatory mechanism of Wy-40,972 in the hypx proestrous rat as evidenced by the dose-dependent inhibition of this effect by PG synthetase inhibitors, indomethacin and Fentiazac. Moreover, there were significant increases in ovarian concentrations of PGF2 alpha and PGE2-PGE1 in response to Wy-40,972 that could be prevented by indomethacin. However, exogenous administration of either of these PG's was not effective in inducing ovulation in the hypx rat.

GnRH agonist-induced inhibitory and stimulatory effects during ovarian follicular maturation

The in vivo regulation of ovarian gonadotropin and prolactin receptors and adenylate cyclase activity by FSH, and the potent GnRH agonist [D-Ala6]des-Gly10-GnRH N-ethylamide (GnRHa), was studied in immature hypophysectomized diethylstilbestrol-implanted rats. During FSH treatment over a 48 h period, FSH receptors increased 2-fold with the maximum response during the first 12 h, whereas LH and prolactin receptors increased by 10-fold and 6-fold with the maximum response from 12 to 48 h. Administration of GnRHa at any time during the 48 h period of FSH treatment inhibited the subsequent development of gonadotropin and PRL receptors. In contrast, administration of a single dose of 10 micrograms GnRHa after 48 h of FSH treatment stimulated follicular luteinization and caused increases in basal adenylate cyclase activity, ovarian weight and PRL receptor content, and concomitant decreases in gonadotropin receptors and adenylate cyclase responses. In the immature follicles of animals not primed with FSH, GnRHa caused progressive inhibition of FSH-sensitive adenylate cyclase activity, with a decrease in FSH receptors, but increased both basal and GMP-P(NH)P-stimulated adenylate cyclase activities. These results demonstrate that GnRHa causes marked inhibition of gonadotropin receptor expression in the basal and FSH-stimulated ovary. This decrease in gonadotropin receptors is an important component of the mechanism by which GnRH agonists inhibit ovarian gonadotropin-sensitive adenylate cyclase activity. In addition, these peptides exert stimulatory effects upon ovarian weight and basal adenylate cyclase activity, and cause an increase in PRL receptors and luteinization of mature ovarian follicles.(ABSTRACT TRUNCATED AT 250 WORDS)

The role of calcium in luteinizing hormone-releasing hormone agonist (ICI 118630)-stimulated steroidogenesis in rat Leydig cells

The luteinizing hormone-releasing hormone (LHRH) agonist ICI 118630 was found to increase testosterone production in purified rat testis Leydig cells in a concentration- and time-dependent manner, but no consistent changes in cyclic AMP levels were detectable. The stimulation of steroidogenesis by LHRH agonist was found to be dependent on the concentration of Ca2+ in the incubation medium; at least 1 mM was required. The calcium ionophore A23187 mimicked the effects of the LHRH agonist on steroidogenesis, and addition of both compounds together did not further increase testosterone production. The calcium ionophore caused a small increase in cyclic AMP which was independent of the concentration of the ionophore and of the calcium concentrations. The evidence obtained in this study indicates that LHRH agonist-stimulated steroidogenesis in rat testis Leydig cells is primarily mediated by calcium and not cyclic AMP.

Gonadotropin-releasing hormone and conception of Holsteins

Effects of gonadotropin-releasing hormone (100 micrograms) and time of artificial insemination on fertility, were examined in lactating dairy cows at first, second, and third services. Inseminations were either soon after detected estrus (0 h) or 12 h later, and cows were given gonadotropin-releasing hormone or saline after inseminations. Conception at first service was not improved by hormone treatment. But conception rates at repeat services were improved by nearly 21% when cows were treated with gonadotropin-releasing hormone within 30 s after insemination. Inseminations soon after detection of estrus (0 h) followed by hormone treatment resulted in the highest conception rates for all services. Time of the insemination (0 versus 12 h) had no effect on conception. Administering gonadotropin-releasing hormone at repeat services should improve conception rate of lactating dairy cows.

The effect of calcium on the potentiation of LH-stimulated steroidogenesis and inhibition of LH-stimulated cyclic AMP production by LHRH agonist (ICI 118630) in rat Leydig cells

A luteinizing hormone-releasing hormone (LHRH) agonist (ICI 118630) potentiated the effects of luteinizing hormone (LH) and dibutyryl cyclic AMP on steroidogenesis during 4 h incubations with rat Leydig cells. LH-stimulated cyclic AMP levels were decreased by the addition of the LHRH agonist. The potentiation of the LH-increased steroidogenesis was dependent on Ca2+; maximum effects required at least 2.5 mM Ca2+ in the incubation medium. The calcium ionophore A23187 negated the potentiation in a dose-dependent manner (ED50 = 0.2-0.3 microM), but had no effect on LH-induced steroidogenesis, despite a 90% decrease in cyclic AMP production. The latter decrease was found to be dependent on the Ca2+ concentration. In the presence of the phosphodiesterase inhibitor methylisobutylxanthine (MIX), the ionophore A23187 induced a dose-dependent decrease in both LH and LH plus LHRH agonist-stimulated steroidogenesis and cyclic AMP production. The results obtained indicate that calcium, rather than cyclic AMP, is the mediator of the potentiating effects of LHRH agonist on LH-increased steroidogenesis in rat Leydig cells. The marked inhibition of the synergism in the presence of calcium ionophore A23187 suggests that Leydig cell calcium homeostasis must be intact for LHRH agonist action to occur. LHRH agonist causes a Ca2+-dependent decrease in LH-stimulated cyclic AMP production.

Proteolytic degradation of gonadotropin-releasing hormone (GnRH) by rat ovarian fractions in vitro

GnRH in physiological concentrations is highly degradable by both soluble and particulate fractions of rat ovarian homogenate in vitro. The two proteolytic enzyme activities differ strongly by the soluble activity showing a dithiothreitol optimum, high inhibition by diisopropyl fluorophospate (ki = 0.7 microM), and a relatively high affinity (Km = 1.1 microM) as opposed to the particulate fraction (Ki = 3.5 mM and Km = 150 microM, respectively). The results of this study show that the rat ovary is differently endowed with GnRH-degrading activity at different sites. The involvement of these in terminating the biological activity of the hormone on the ovary may possibly depend on its exact pathway in this GnRH-target organ.

Dissociation between the direct stimulatory and inhibitory effects of a gonadotropin-releasing hormone analog on ovarian functions

The paradoxical effects of gonadotropin-releasing hormone (GnRH) on the ovary have hitherto been believed to result from different regimens of administration; an acute treatment was shown to stimulate the ovary while chronic administration of the hormone inhibited LH-induced responses. In the present report we demonstrate that a single injection of a GnRH analog (D-Ala6)des-Gly10-GnRH-N-ethylamide (GnRHa, 2 micrograms/rat) is sufficient to obtain a significant inhibition (75%) of hCG-induced ovulation in PMSG-primed, either intact or hypophysectomized, immature rats. Inhibition of ovarian development, in terms of growth and ovulation, by multiple injections with GnRHa (2 micrograms/rat, twice daily for 3 days) could be obtained only upon administration of the hormone at early stages of follicular development, i.e. concomitantly with the PMSG injection. When administered after PMSG, GnRHa could not inhibit the ovary but rather induced ovulation by itself in the absence of hCG. A 12-24 h delay in initiation of GnRHa treatment triggered 65% of the rats to ovulate while a delay of 48 h resulted in 100% ovulation. Under both regimes of GnRHa administration, either the inhibitory or the stimulatory, the oocytes of the treated rats were induced to resume meiotic maturation. Since under the inhibitory regime ovulation did not occur, maturation was followed by a massive degeneration of the oocytes trapped within their follicles. These findings demonstrate that the follicular stage of development rather than the dose and/or duration of GnRHa administration determines whether GnRHa inhibits ovarian growth and ovulation, while the competence of the oocytes to respond to the GnRHa stimulus and mature is independent of hormonal priming.

Stimulation of androstenedione and progesterone release by LHRH and LHRH agonist from isolated rat preovulatory follicles

Incubation of preovulatory rat follicles isolated from PMSG-treated immature rats for periods of less than 24 h in the presence of LHRH or LHRH agonist resulted in stimulation of basal androstenedione and progesterone release. The stimulatory effects seen were time-dependent, occurring from 2-3 h for androstenedione and from 8-20 h incubation for progesterone. Dose-dependent stimulation occurred with both LHRH agonist (in the range 5 X 10(-10) to 10(-8) M) and native LHRH (from 10(-9) to 10(-6) M), both being in the range of the reported Ka for ovarian LHRH receptors. LHRH did not enhance the stimulatory effect of 1-100 mIU hCG on androstenedione and progesterone release. These results show for the first time that LHRH and LHRH agonist can exert a stimulatory action on androgen release from isolated preovulatory follicles. This suggests that LHRH may be acting either directly at the thecal cell level or indirectly via decreased granulosa cell aromatization.

The regulation of LHRH action at the pituitary and gonadal receptor level: a review

Luteinizing hormone releasing-hormone (LHRH) and its highly active agonists are under clinical investigation for the control of reproductive function and for suppression of hormone dependent tumours. The regulation of LHRH action by pituitary receptors and expression of the biological LHRH effect by gonadotropin release and activation of steroid biosynthesis are discussed in this context. Pituitary LHRH receptors are controlled by autoregulation via endogenous LHRH secretion. The gonadal response to LHRH stimulation is regulated by LH action on receptors for LH, prolactin and FSH. Pituitary and gonadal inhibition are achieved by different mechanisms. Continuous exposure to LHRH blocks gonadotropin release and reduces pituitary LH/FSH content, whereas inhibition of steroid biosynthesis requires daily LH release to maintain receptor down-regulation. Pituitary enzymes involved in LHRH degradation at the receptor site are required for terminating hormone action, but their role in modulating hormonal responsiveness is secondary to receptor regulation. Direct gonadal effects of LHRH are exerted in the presence of gonadotropins by modulating the gonadotropin effect, e.g. in hypophysectomized animals. The presence of specific receptors for LHRH agonists in ovarian and testicular tissue suggests local control mechanisms for gonadotropin activation of steroid biosynthesis.

GnRH receptors in cultured rat granulosa cells: mediation of the inhibitory and stimulatory actions of GnRH

The regulatory actions of FSH and the GnRH agonist [D-Ala6]des-Gly10-GnRH N-ethylamide (GnRHa) upon ovarian GnRH receptors were studied in granulosa cells obtained from ovaries of hypophysectomized diethylstilbestrol-treated rats. When granulosa cells were cultured for 48 h in the presence of FSH (5-250 ng/ml) the binding of 125I-GnRHa to granulosa cell receptors was increased in a dose-dependent manner, to a maximum of 3-4 fold above the control value. Addition of FSH (100 ng) also caused a dose-dependent increase of more than 100-fold in the accumulation of cAMP and progesterone in the culture medium. In freshly prepared cells, Scatchard analysis of GnRHa binding data revealed an equilibrium constant (Ka) of 1.1 x 10(10) M-1 and GnRH receptor concentration fo 401 fmoles/mg protein. Granulosa-cell GnRH receptors decreased during culture without FSH, but were maintained in the presence of 100 ng FSH at 580 femoles/mg protein, with Ka of 0.8 x 10(10) M-1. This action of FSH on GnRH receptors was significantly reduced by 10(-8) M GnRHa. Also, GnRHa concentrations of 10(-10) and 10(-8) M caused inhibition of FSH-induced cAMP and progesterone accumulation. In cells cultured with GnRHa alone, there was a slight enhancement of GnRH receptors by GnRHa concentrations up to 10(-8) M, and a decrease below control levels with higher amounts. Also, GnRHa concentrations from 10(-8) to 10(-5) M caused a 3-4-fold increase in cAMP accumulation in the absence of FSH. These results demonstrate that FSH maintains GnRH receptors in cultured granulosa cells, and that GnRHa attenuates this effect, as well as the other actions of FSH on granulosa cell maturation. It is also evident that GnRHa itself can slightly stimulate cAMP production and partially maintain GnRH receptors, but at high concentrations causes loss of the homologous receptor sites. These findings also emphasize the ability of GnRH agonists to exert both positive and negative direct effects on rat granulosa cell function.

Resistance of the mouse to the antifertility effects of LHRH agonists

In the mouse, the LH-releasing activity of the LHRH agonist, D-Trp6-N alpha-MeLeu7-DesGly10-Pro9-NHEt-LHRH (Wy-40,972), was established by its ability both to induce ovulation when administered at 1600 hours on the the second day of diestrus and to elevate serum LH in adult males. While Wy-40,972 was only slightly less active in terms of these and points than it was in the rat, the predictive and possibly causal association between LH-releasing and antifertility activity established for this LHRH analog in the rat could not be clearly identified in the mouse. A total daily dose of 1000 microgram Wy-40,972/mouse was required to completely inhibit pregnancy during days 1-7 of pregnancy and produced only partial inhibition during days 7-12. This dose represents, on a body weigh basis, 8250 times the 100 percent effective pregnancy-terminating dose for the rat during equivalent intervals. The resistance of the mouse to the antifertility activity of Wy-40,972 was found not to be restricted to this particular LHRH analog or to the reproductive state. Administration of another potent LHRH analog, D-Ala6-DesGly10-Pro9-NHEt-LHRH (Wy-18,481), to adult male mice at a dose of 100 microgram/mouse/day for up to 14 days had no inhibitory effect on the weights of the testes or sex accesory organs. This dose of Wy-18,481 is 7500 times that necessary for significant reduction of these reproductive organ weights in rats within 7 days of treatment. Investigation as to the nature of the mouse's apparently divergent response to the LHRH agonists may further elucidate the antifertility mechanism of such compounds in susceptible species.